Close Menu
Home » Asuragen, Wave Life Sciences to Develop Companion Diagnostics for Huntington's Disease Therapies

Asuragen, Wave Life Sciences to Develop Companion Diagnostics for Huntington's Disease Therapies

Nov 25, 2019
|
staff reporter

NEW YORK – Molecular diagnostics company Asuragen announced on Monday that it is collaborating with genetic medicines developer Wave Life Sciences to develop and commercialize companion diagnostics for Wave's investigational allele-selective therapeutic programs for Huntington's disease.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Nobel Representation

In a cartoon, Vox explores the lack of women among this year's winners of the Nobel Prize.

Bill to Address Foreign Influence

Science reports a new US defense bill would establish two groups aimed at combating foreign influence on research. 

Promising, But More Needed

Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.

Cell Studies Tackle Tissue Clones, Ocean Microbes, Polygenic Trait Prediction

In Cell this week: analysis of tissue clones, metagenomic studies of ocean water samples, and more.

What's Popular?

In Business News

  1. Bio-Rad Shares Dip Following Cyber Attack

  2. Celmatix Sues 23andMe for $100M Alleging Breach of Contract

  3. Parkinson's Foundation Selects Five Sites for Genetic Testing, Counseling

  4. Forensic Genomics Firm Verogen Acquires Genealogy Website GEDmatch

  5. GenMark Diagnostics Downgraded by JP Morgan to Neutral

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.